share_log

BeyondSpring (NASDAQ:BYSI) Shares Up 0.7%

BeyondSpring (NASDAQ:BYSI) Shares Up 0.7%

萬春醫藥(納斯達克:BYSI)股價上漲0.7%
Financial News Live ·  2022/08/10 18:31

BeyondSpring Inc. (NASDAQ:BYSI – Get Rating)'s share price shot up 0.7% during trading on Monday . The stock traded as high as $1.57 and last traded at $1.52. 165,615 shares traded hands during trading, a decline of 59% from the average session volume of 403,071 shares. The stock had previously closed at $1.51.

納斯達克週一盤中股價飆升0.7%,盤中一度漲至1.57美元,最新報1.52美元。當日有165,615股股票易手,較403,071股的日均成交量下跌59%。此前該股收盤價為1.51美元。

BeyondSpring Stock Performance

萬春醫藥股票表現

The company has a market capitalization of $57.23 million, a PE ratio of -0.88 and a beta of 1.04. The firm has a fifty day moving average of $1.52 and a two-hundred day moving average of $1.94.

該公司市值為5723萬美元,市盈率為-0.88,貝塔係數為1.04。該公司的50日移動均線切入位在1.52美元,200日移動均線切入位在1.94美元。

Get
到達
BeyondSpring
萬春醫藥
alerts:
警報:

Institutional Investors Weigh In On BeyondSpring

機構投資者在萬春醫藥上發表看法

Several institutional investors have recently bought and sold shares of BYSI. Walleye Capital LLC purchased a new stake in BeyondSpring during the 1st quarter valued at about $28,000. Mirabella Financial Services LLP purchased a new stake in BeyondSpring during the 1st quarter valued at about $44,000. Orion Portfolio Solutions LLC purchased a new stake in BeyondSpring during the 2nd quarter valued at about $44,000. Fox Run Management L.L.C. purchased a new stake in BeyondSpring during the 4th quarter valued at about $56,000. Finally, Acadian Asset Management LLC purchased a new stake in BeyondSpring during the 1st quarter valued at about $76,000. 18.89% of the stock is currently owned by hedge funds and other institutional investors.

幾家機構投資者最近買賣了比亞迪的股票。Walleye Capital LLC在第一季度購買了萬春醫藥的新股份,價值約28,000美元。米拉貝拉金融服務有限責任公司在第一季度購買了萬春醫藥的新股份,價值約44,000美元。獵户座投資組合解決方案有限責任公司在第二季度購買了萬春醫藥的新股份,價值約44,000美元。狐狸奔跑管理有限公司在第四季度購買了萬春醫藥的新股份,價值約56,000美元。最後,阿卡迪亞資產管理有限責任公司在第一季度購買了萬春醫藥的新股份,價值約76,000美元。18.89%的股票目前由對衝基金和其他機構投資者持有。

About BeyondSpring

關於萬春醫藥

(Get Rating)
(獲取評級)

BeyondSpring Inc, a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer.

萬春醫藥是一家臨牀期生物製藥公司,與其子公司一起專注於癌症療法的開發。該公司的主要資產是普利布林,這是一種選擇性免疫調節微管結合劑,已經完成了預防化療引起的中性粒細胞減少症和治療晚期非小細胞肺癌的第三階段臨牀試驗。

Featured Stories

專題報道

  • Get a free copy of the StockNews.com research report on BeyondSpring (BYSI)
  • The How And Why of Investing in Oil Stocks
  • The How and Why of Investing in Gold Stocks
  • A Rounded Bottom In Draftkings, Inc Begins To Reverse Course
  • Workhorse Group Is Ready To Get Back On The Horse
  • Are 3M, Honeywell, GE Buys After Quarterly Reports?
  • 在新浪萬春醫藥上免費獲取斯托克新聞網的研究報告
  • 投資石油股票的方式和原因
  • 投資黃金股票的方式和原因
  • DraftKings,Inc.的圓底開始逆轉
  • 工作馬集團準備重返賽馬
  • 3M、霍尼韋爾、通用電氣在季度報告後收購嗎?

Receive News & Ratings for BeyondSpring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring and related companies with MarketBeat.com's FREE daily email newsletter.

接受萬春醫藥日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收最新新聞和分析師對萬春醫藥及相關公司評級的每日摘要。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論